Product Name :
RIPA-56
Description:
RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interactingprotein 1 (RIP1) with an IC50 of 13 nM. RIPA-56 can be used for the treatment of systemic inflammatory response syndrome.
CAS:
1956370-21-0
Molecular Weight:
221.30
Formula:
C13H19NO2
Chemical Name:
N-benzyl-N-hydroxy-2,2-dimethylbutanamide
Smiles :
CCC(C)(C)C(=O)N(O)CC1C=CC=CC=1
InChiKey:
AVYVHIKSFXVDBG-UHFFFAOYSA-N
InChi :
InChI=1S/C13H19NO2/c1-4-13(2,3)12(15)14(16)10-11-8-6-5-7-9-11/h5-9,16H,4,10H2,1-3H3
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
RIPA-56 is a highly potent, selective, and metabolically stable inhibitor of receptor-interactingprotein 1 (RIP1) with an IC50 of 13 nM. RIPA-56 can be used for the treatment of systemic inflammatory response syndrome.|Product information|CAS Number: 1956370-21-0|Molecular Weight: 221.30|Formula: C13H19NO2|Chemical Name: N-benzyl-N-hydroxy-2,2-dimethylbutanamide|Smiles: CCC(C)(C)C(=O)N(O)CC1C=CC=CC=1|InChiKey: AVYVHIKSFXVDBG-UHFFFAOYSA-N|InChi: InChI=1S/C13H19NO2/c1-4-13(2,3)12(15)14(16)10-11-8-6-5-7-9-11/h5-9,16H,4,10H2,1-3H3|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Solubility: DMSO : ≥ 100 mg/mL (451.88 mM).|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|RIPA-56 shows efficient inhibition of RIP1 kinase activity, with an IC50 of 13 nM and no inhibition of RIP3 kinase activity at a 10 μM concentration.Itepekimab medchemexpress RIPA-56 also demonstrates potency in protection of murine L929 cells from TNFα/z-VAD-FMK (TZ)-induced necrosis (EC50=27 nM).Aspirin custom synthesis |In Vivo:|In the SIRS mice disease model, RIPA-56 efficiently reduces tumor necrosis factor alpha (TNFα)-induced mortality and multi-organ damage.PMID:33280428 Compared to known RIP1 inhibitors, RIPA-56 is potent in both human and murine cells, is much more stable in vivo, and is efficacious in animal model studies. RIPA-56 has an impressive PK profile in mice with a 3.1 h half-life, 22% oral bioavailability (P.O.), and 100% bioavailability from intraperitoneal injection (I.P.).|Products are for research use only. Not for human use.|